4.7 Meeting Abstract

Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study

Journal

ANNALS OF ONCOLOGY
Volume 32, Issue -, Pages S1330-S1330

Publisher

ELSEVIER
DOI: 10.1016/j.annonc.2021.08.2132

Keywords

-

Categories

Funding

  1. Innovent Biologics, Inc., China
  2. Eli Lilly and Company, US

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available